Open Nav

Please submit your session questions in advance at

Bioasis Technologies Inc.

  • Mark Day, Bioasis Technologies Inc.

Bioasis Technologies Inc. is a biopharmaceutical company developing the xB³ ™ platform, a proprietary technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. Bioasis maintains headquarters in Guilford, Conn., United States. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.”

  • Date:Monday, February 11
  • Time:1:15 PM - 1:30 PM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23346
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Introduce Bioasis and the xB³ platform technology to new investors and potential partners.
  • Company Website:
  • Company HQ City:Guilford
  • Company HQ State:Connecticut
  • Company HQ Country:United States
  • Ticker:BTI
  • Exchange:TSX Venture Exchange
  • CEO/Top Company Official:Mark Day, Ph.D., Director, President & Chief Executive Officer
  • Year Founded:2007
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:xB³-001 (HER2+ breast cancer brain metastases)
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):4
  • Additional Information/Comments:The delivery of therapeutics across the blood-brain barrier represents the final frontier in treating neurological disorders. The xB³ platform technology is a non-invasive, multi-modal solution to the problem of transporting complex therapeutic molecules across the BBB. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. The xB³ platform has advantages over other BBB technologies in terms of payload flexibility and efficiency of delivery. Pre-clinical studies demonstrated delivery of large antibodies, small molecules, enzyme replacement therapies and siRNA. The Company is also actively pursuing licensing and business development opportunities for the advancement of external neuroscience and oncology programs.
Mark Day
Bioasis Technologies Inc.